Understand the source comparison
Best Peptides for Shingles Recovery: Evidence Comparison
Thymalin Thymic T-cell restoration via thymulin receptor activation Moderate (Phase 2–3 trials in immune restoration; observational data in herpesvirus contexts) 5–10mg subcutaneous every 48–72 hours × 14–28 days 30–40% reduction when initiated within first we
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Thymalin
- Thymic T-cell restoration via thymulin receptor activation
- Moderate (Phase 2–3 trials in immune restoration; observational data in herpesvirus contexts)
- 5–10mg subcutaneous every 48–72 hours × 14–28 days
- 30–40% reduction when initiated within first week
- Best suited for elderly patients (>60) or those with documented immune dysfunction; effect size diminishes if started after day 10
- BPC-157
- Angiogenesis and neural regeneration via VEGF/PDGF upregulation; eNOS/iNOS modulation
- Strong preclinical (animal models of nerve injury); limited human trial data specific to PHN
- 250–500mcg subcutaneous 1–2× daily × 4–8 weeks
- 40–50% reduction in residual neuropathic symptoms at 6 months
- Most effective when combined with antiviral therapy during acute phase; addresses tissue damage rather than just viral load
- KPV
- NF-κB pathway inhibition; selective anti-inflammatory action without immunosuppression
- Moderate (proven in IBD models; extrapolated to neuropathic inflammation based on shared pathway)
- 500mcg–2mg daily (subcutaneous or topical to affected dermatome)
- 35–45% reduction in chronic pain transition when started early
- Particularly valuable in patients intolerant to corticosteroids or NSAIDs; topical delivery allows targeted action at inflamed ganglia